2024年美国临床肿瘤学会（ASCO）年会将于当地时间2024年5月31日至6月4日在美国芝加哥盛大召开。作为肿瘤领域最具权威性的年度盛会，全球肿瘤学领域的多项重磅研究将于此次大会公布结果。现在2024年ASCO会议的讨论题目已经公开，中枢神经系统肿瘤的重磅研究有哪些？【肿瘤资讯】整理如下，以飨读者
Oral Abstract Session
摘要号：2000
标题：N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.
N2M2/NOA-20：分子靶向治疗加放疗治疗无MGMT启动子高甲基化的新诊断胶质母细胞瘤患者的I/IIa期伞形试验
讲者/第一作者：Wolfgang Wick，University of Heidelberg
摘要号：2001
标题：Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations.
Alliance A071401：阿贝西利在伴有体细胞NF2或CDK通路改变的2/3级脑膜瘤患者中的II期试验
讲者/第一作者：Priscilla Brastianos，Massachusetts General Hospital, Harvard Medical School
摘要号：2002
标题：Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0/2 "trigger" trial.
尼拉帕利在新诊断胶质母细胞瘤患者中的疗效：0/2期“触发”试验的临床结果
讲者/第一作者：Nader Sanai，Ivy Brain Tumor Center at Barrow Neurological Institute
摘要号：2003
标题：Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPRZ1-METFUsion GENe (FUGEN): A randomised, multicentre, open-label, phase II/III trial.
伯瑞替尼在既往接受过治疗的继发性胶质母细胞瘤/携带PTPRZ1—METFUsion基因（FUGEN）的IDH突变型胶质母细胞瘤患者中的疗效和安全性：一项随机、多中心、开放标签、II/III期试验
讲者/第一作者：江涛，北京市神经外科研究所
摘要号：2004
标题：Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma.
IDH突变型1 p/19 q共缺失3级少突胶质细胞瘤患者一线PCV或替莫唑胺联合放疗的生存结局
讲者/第一作者：Salah Eddine Kacimi，Paris Brain Institute (ICM)
摘要号：2005
标题：Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.
VAL-083在一项针对新诊断和复发性胶质母细胞瘤的III期注册平台试验GBM AGILE中的评价
讲者/第一作者：John de Groot，University of California, San Francisco
摘要号：2006
标题：A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).
一项阿基仑赛（axi-cel）治疗复发性/难治性原发性和继发性中枢神经系统淋巴瘤（PCNSL和SCNSL）的初探性研究
讲者/第一作者：Lakshmi Nayak，Dana-Farber Cancer Institute
摘要号：2007
标题：High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis.
高剂量阿美替尼治疗EGFR突变NSCLC初治患者的疗效和生物标志物分析
讲者/第一作者：范云，浙江省肿瘤医院
摘要号：2008
标题：Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.
一项国际、多中心III期随机METIS（EF-25）研究，旨在评价肿瘤治疗电场（TTFields）治疗NSCLC脑转移患者的疗效和安全性
讲者/第一作者：Minesh Mehta，Miami Cancer Institute, Baptist Health South Florida
Clinical Science Symposium
摘要号：2009
标题：Longitudinal tumor-wide sampling of glioblastoma reveals diverse genomic drivers of the earliest clonal expansion at diagnosis and recurrence.
胶质母细胞瘤的纵向肿瘤范围取样揭示了诊断和复发时最早克隆扩增的不同基因组驱动因素
讲者/第一作者：Benjamin Lerman，University of California, San Francisco
摘要号：2010
标题：Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high grade glioma.
脑脊液循环肿瘤DNA（ctDNA）对复发性高级别胶质瘤患者预后的作用
讲者/第一作者：Bridget Holle，Memorial Sloan Kettering Cancer Center
摘要号：2011
标题：Efficacy and biomarker analysis of phase 2 (P2) and window-of-opportunity (WoO) cohorts of patients with recurrent glioblastoma (rGBM) treated with ST101, an inhibitor of the transcription factor C/EBPβ.
接受转录因子C/EBP β抑制剂ST 101治疗的复发性胶质母细胞瘤（rGBM）患者的II期（P2）和机会窗（WoO）队列的疗效和生物标志物分析
讲者/第一作者：Fabio Iwamoto，Columbia University Irving Medical Center
摘要号：2012
标题：Pre-clinical modeling of navtemadlin pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in glioblastoma, IDH-wildtype.
navtemadlin药代动力学（PK）、药效学（PD）和在胶质母细胞瘤（IDH-野生型）中疗效的临床前建模
讲者/第一作者：Rachael Vaubel，Mayo Clinic
Rapid Oral Abstract Session
摘要号：2013
标题：A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas.
奥拉帕利和度伐利尤单抗在复发性IDH突变胶质瘤患者中的II期试验
讲者/第一作者：Xin Wang，Princess Margaret Cancer Centre
摘要号：2014
标题：Phase 2 trial of pembrolizumab plus SurVaxM for patients with glioblastoma at first recurrence (RESURGe).
帕博利珠单抗联合SurVaxM治疗首次复发胶质母细胞瘤患者的II期试验（RESURGe）
讲者/第一作者：Manmeet Ahluwalia，Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic
摘要号：2015
标题：A phase Ib, window-of-opportunity study of neoadjuvant avelumab and hypofractionated proton beam therapy for recurrent radiation-relapsed meningioma.
一项新辅助阿维鲁单抗和大分割质子束治疗复发的放射性复发性脑膜瘤的Ib期、机会窗研究
讲者/第一作者：Jiayi Huang，Washington University School of Medicine in St. Louis
摘要号：2016
标题：Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).
评价MN-166（异丁司特）和替莫唑胺联合治疗新诊断和复发性胶质母细胞瘤（GBM）患者的Ib/IIa期研究
讲者/第一作者：Gilbert Youssef，Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School
摘要号：2017
标题：A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
在新诊断的胶质母细胞瘤（GBM）患者（pts）中进行的一项关于脑组织中brigimadlin浓度的0/Ia期（Ph）研究和一项关于brigimadlin联合放疗（RT）的非随机、开放标签、剂量递增研究
讲者/第一作者：Jann Sarkaria，Mayo Clinic
摘要号：2018
标题：Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.
Tucatinib-曲妥珠单抗-卡培他滨治疗HER 2+乳腺癌的软脑膜转移：TBCRC 049 II期研究结果
讲者/第一作者：Barbara O'Brien，The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology
摘要号：2019
标题：Tyrosine kinase inhibitors with and without upfront CNS radiation for brain metastases in oncogene-driven non-small cell lung cancer (TURBO-NSCLC).
酪氨酸激酶抑制剂联合或不联合前CNS放疗治疗癌基因驱动的非小细胞肺癌（TURBO-NSCLC）脑转移
讲者/第一作者：Emily Miao，Albert Einstein College of Medicine
摘要号：2020
标题：Stereotactic radiosurgery in patients with small cell lung cancer and 1-10 brain metastases: A multi-institutional, phase II, prospective clinical trial.
小细胞肺癌伴1-10处脑转移患者的立体定向放射外科治疗：一项多机构、II期、前瞻性临床试验
讲者/第一作者：Ayal Aizer，Brigham and Women's Hospital/Dana-Farber Cancer Institute
摘要号：2021
标题：Re-irradiation in recurrent glioblastoma: PET- or MRI-based? Results of a prospective randomized clinical trial.
复发性胶质母细胞瘤的再照射：基于PET还是MRI？ 前瞻性随机临床试验的结果
讲者/第一作者：Ilinca Popp，Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine
排版编辑：肿瘤资讯-云初
苏公网安备32059002004080号
